Showing results (101-110 of 175) with videos related to

Sort By:
Pageof 18
Molecular Cancer Therapeutics|May 29, 2025
Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR MutationSachi Okawa, Shuta Tomida, Tadahiro Kuribayashi, et al.
Molecular Oncology|April 8, 2017
Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivoKenichiro Kudo, Kadoaki Ohashi, Go Makimoto, et al.
Biochemical and Biophysical Research Communications|September 5, 2020
Beneficial effect of erlotinib and trastuzumab emtansine combination in lung tumors harboring EGFR mutationsHiroe Kayatani, Kadoaki Ohashi, Kiichiro Ninomiya, et al.
Thoracic Cancer|May 3, 2024
Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR-mutated lung cancer and pulmonary tuberculosis: A case reportHiroaki Matsuura, Hisao Higo, Tadahiro Kuribayashi, et al.
Heliyon|May 3, 2024
Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysissDavid J H Bian, Anna-Maria Lazaratos, Sarah M Maritan, et al.
Cancer Research|April 2, 2013
Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cellsKazuhiko Shien, Shinichi Toyooka, Hiromasa Yamamoto, et al.
Cancers|December 23, 2022
The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational StudyTomoka Nishimura, Eiki Ichihara, Toshihide Yokoyama, et al.
International Journal of Cancer|August 23, 2023
Low frequency of intracranial progression in advanced NSCLC patients treated with cancer immunotherapiesNaoya Kemmotsu, Kiichiro Ninomiya, Kei Kunimasa, et al.
International Journal of Clinical Oncology|August 28, 2025
Impact of antibiotic use on survival in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitor and chemotherapyNobuaki Ochi, Eiki Ichihara, Toshihide Yokoyama, et al.
International Journal of Clinical Oncology|May 9, 2022
Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801Shinobu Hosokawa, Eiki Ichihara, Daijiro Harada, et al.
Pageof 18